Company Overview and News

 
What's in the Offing for Grainger (GWW) in Q1 Earnings?

2018-04-17 zacks
W.W. Grainger, Inc. (GWW - Free Report) is scheduled to report first-quarter 2018 results before the market opens on Apr 19. In the last quarter, Grainger posted earnings of $2.94 per share, beating the Zacks Consensus Estimate by a wide margin of around 35%. The company’s earnings also surpassed estimates in three out of the trailing four quarters, recording an average positive earnings surprise of roughly 12%.
Upvote Downvote

 
TPIC / TPI Composites, Inc. FORM 8-K (Current Report)

2018-04-09 sec.gov
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
Upvote Downvote

 
TPIC / TPI Composites, Inc. DEFINITIVE ADDITIONAL MATERIALS

2018-04-04 sec.gov
Definitive Additional Materials UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
Upvote Downvote

 
TPIC / TPI Composites, Inc. DEF 14A

2018-04-04 sec.gov
DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20
Upvote Downvote

 
TPIC / TPI Composites, Inc. 8-K (Current Report)

2018-03-19 sec.gov
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
Upvote Downvote

 
TPI and Vestas Sign Wind Blade Supply Agreement to Open New Facility in China

2018-03-19 globenewswire
SCOTTSDALE, Ariz., March 19, 2018 (GLOBE NEWSWIRE) -- TPI Composites, Inc., (TPI) (Nasdaq:TPIC), the largest U.S.-based independent manufacturer of composite wind blades, announced today that it has signed a multiyear supply agreement with Vestas Wind Systems A/S to provide blades from four manufacturing lines (with option to add more lines) for the new V150-4.2 MW wind turbine for global markets. The blades will be produced at a new facility in Yangzhou, Jiangsu, China, which is scheduled to open for production in the first half of 2019.
Upvote Downvote

 
TPIC / TPI Composites, Inc. FORM S-8

2018-03-12 sec.gov
Form S-8 As filed with the Securities and Exchange Commission on March 12, 2018 Registration No. 333-
Upvote Downvote

 
Navistar Partners With TPI to Develop Lighter Class 8 Trucks

2018-03-12 zacks
Navistar International Corporation ((NAV - Free Report) ) signed an agreement with TPI Composites, Inc. ((TPIC - Free Report) ) to design and develop Class 8 trucks, enabled with frame rails and composite tractor. This recent collaboration took place after Navistar received an award under the U.S. Department of Energy’s Super Truck II investment program. The program is intended to promote fuel efficiency in commercial vehicles.
Upvote Downvote

1
TPI Composites' (TPIC) CEO Steve Lockard on Q4 2017 Results - Earnings Call Transcript

2018-03-09 seekingalpha
Good afternoon and welcome to the TPI Composites’ Fourth Quarter and Full Year 2017 Earnings Conference Call. Today’s call is being recorded and we have allocated an hour for prepared remarks and Q&A. At this time, I would like to turn the conference over to Anthony Rozmus, Investor Relations for TPI Composites. Thank you, sir. Please go ahead.
Upvote Downvote

 
TPI Composites 2017 Q3 - Results - Earnings Call Slides

2018-03-09 seekingalpha
The following slide deck was published by TPI Composites in conjunction with their 2017 Q3 earnings call.
Upvote Downvote

 
BRIEF-TPI To Collaborate With Navistar To Design And Build Trucks

2018-03-08 reuters
* TPI COMPOSITES - ENTERED INTO AGREEMENT WITH NAVISTAR, INC. TO DESIGN AND DEVELOP A CLASS 8 TRUCK COMPRISED OF A COMPOSITE TRACTOR AND FRAME RAILS Source text for Eikon: Further company coverage:
Upvote Downvote

 
TPIC / TPI Composites, Inc. 10-K (Annual Report)

2018-03-08 sec.gov
tpic-10k_20171231.htm UNITED STATES
Upvote Downvote

 
TPIC / TPI Composites, Inc. FORM 8-K (Current Report)

2018-03-08 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________ Form 8-K _____________________ CURRENT REPORT
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...

CUSIP: 87266J104